• español
    • English
  • Login
  • English 
    • español
    • English

UniversidaddeCádiz

Área de Biblioteca, Archivo y Publicaciones
Communities and Collections
View Item 
  •   RODIN Home
  • Producción Científica
  • Artículos Científicos
  • View Item
  •   RODIN Home
  • Producción Científica
  • Artículos Científicos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

RhoA in aneurysmal subarachnoid hemorrhage

Thumbnail
Identificadores

URI: http://hdl.handle.net/10498/31634

DOI: 10.18632/aging.101819

Files
Editorial (281.5Kb)
Statistics
View statistics
Metrics and citations
 
Share
Export
Export reference to MendeleyRefworksEndNoteBibTexRIS
Metadata
Show full item record
Author/s
Ureña, Juan; González Montelongo, María del CarmenAuthority UCA; Murillo Cabezas, Francisco
Date
2019
Department
Biomedicina, Biotecnología y Salud Pública
Source
Aging. 2019;11(4):1079-1080.
Abstract
Aneurysmal subarachnoid haemorrhage (aSAH) is a severe subtype of stroke, mediated by the spontaneous rupture of an intracranial aneurysm, that frequently occurs in people between 40 and 60 years of age. Cerebral vasospasm (CV), and related delayed cerebral ischemia (DCI), is a clinical syndrome of the focal neurologic deficits that develop typically three to fourteen days after the aneurysm rupture, and is a major cause of death and disability after aSAH. Vascular constriction and inflammation, more specifically leukocyte-endothelium interaction, appear to play a critical role in CV. Although the main focus of pharmacological treatment of aSAH is the prevention of DCI, the only pharmacological drug shown to reduce the risk of DCI and unfavourable outcome is nimodipine, an L-type Ca2+ channels (LTCCs) antagonist, which does not alter the incidence or severity of CV [1]. On the other hand, although inflammatory biomarkers that facilitate leukocyte-endothelium interaction have been found in the cerebral spinal fluid and serum of patients [2], none of these biomarkers have been shown to be useful tools for predicting CV development or outcome after aSAH. Therefore, it is necessary to study new pathophysiological pathways to improve outcomes and management of patients.
Subjects
RhoA; biomarker; cerebral vasospasm; human mononuclear cells; subarachnoid haemorrhage
Collections
  • Artículos Científicos [12009]
  • Articulos Científicos Biomedicina [582]
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional

Browse

All of RODINCommunities and CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics

Información adicional

AboutDeposit in RODINPoliciesGuidelinesRightsLinksStatisticsNewsFrequently Asked Questions

RODIN is available through

OpenAIREOAIsterRecolectaHispanaEuropeanaBaseDARTOATDGoogle Academic

Related links

Sherpa/RomeoDulcineaROAROpenDOARCreative CommonsORCID

RODIN está gestionado por el Área de Biblioteca, Archivo y Publicaciones de la Universidad de Cádiz

Contact informationSuggestionsUser Support